Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

ORIC Pharmaceuticals  (Stock symbol: ORIC )

240 E. Grand Ave 2nd Floor
So. San Francisco, CA 94080
USA
(650) 388-5600
Website Company Summary Management Team
Management

CEO: Jacob Chacko (5/7/2018)
General Management: Julio Medina
Finance: Sara Coblin (2016) ; Dominic Piscitelli (9/16/2019)
Technology: Valeria Fantin (8/31/2015)
General Counsel/Legal: Christian Kuhlen
Board

Outside board: (May no longer be on the board) Lawrence Lasky (The Column Group Partner) Richard Heyman (ORIC Pharmaceuticals Chairman) Carl L. Gordon (OrbiMed Founding Partner) Leo Guthart (Topspin Partners Managing Partner) Peter Svennilson (The Column Group Managing Partner) Richard H. Scheller (23andMe Chief Science Officer) Mardi C. Dier (Ultragenyx Pharmaceuticals)
Company

Business description: ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego,
Capital

Rounds: 2
Recent Fundings: Dec 2015   Nov 2014
Capital raised: 67.0M
Last Round: 53.0M
Ownership: Public   Ipo Filing
Stock Symbol: ORIC

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2021
Sector: Medical
Headcount: 51-75 as of Jul 2021
Rounds: 2
Recent Fundings: Dec 2015   Nov 2014
Capital Raised: 67.0M
Last Round: 53.0M
Ownership: Public   Ipo Filing
Stock Symbol: ORIC